Apomine, an inhibitor of HMG-COA-reductase, does not act by inhibiting protein prenylation in human myeloma cells in vitro

Apomine, an inhibitor of HMG-COA-reductase, does not act by inhibiting protein prenylation in human myeloma cells in vitro

Bibliographic Details
Main Authors:	Roelofs, A, Hulley, P, Meijer, A, Croucher, P, Russell, R, Shipman, C
Format:	Conference item
Published:	2005

Similar Items

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
by: Edwards, C, et al.
Published: (2007)

The bisphosphonate-ester apornine does not act by inhibiting protein prenylation, but enhances the effects of lovastatin on myeloma cells
by: Roelofs, A, et al.
Published: (2006)

Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
by: Roelofs, A, et al.
Published: (2007)

HMG CoA reductase inhibitors in the treatment of hypercholesterolaemias.
by: Aronson, J, et al.
Published: (1990)

Novel insights into the anti-tumour mechanism of action of apomine and its synergistic interaction with lovastatin in myeloma cells in vitro
by: Roelofs, A, et al.
Published: (2006)

Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells.
by: Roelofs, A, et al.
Published: (2006)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
by: Croucher, P, et al.
Published: (2002)

Targeting Enterococcus faecalis HMG-CoA reductase with a non-statin inhibitor
by: Sucharita Bose, et al.
Published: (2023-04-01)

Effects of HMG-CoA Reductase Inhibitors (Statins) On Bone Mineral Density and Metabolism
by: Nehir Samancı, et al.
Published: (2004-06-01)

The prenyltransferase UBIAD1 is the target of geranylgeraniol in degradation of HMG CoA reductase
by: Marc M Schumacher, et al.
Published: (2015-03-01)

Risedronate, and its phosphonocarboxylate analogue NE10790, both induce apoptosis, but have differential effects on the cell cycle and protein prenylation in human myeloma cells.
by: Roelofs, A, et al.
Published: (2004)

In silico analysis of Mentha pipertia (phyto-constituents) as HMG coa reductase and squalene synthase inhibitors
by: Narayanaswamy, Radhakrishnan, et al.
Published: (2018)

Simvastatin: In Vitro Metabolic Profiling of a Potent Competitive HMG-CoA Reductase Inhibitor
by: Wencui Yin, et al.
Published: (2022-11-01)

An Assessment of Oral Health in Hypertensive Patients Treated with HMG-CoA Reductase Inhibitors (Statins)
by: Amir AM Al-Joboury, et al.
Published: (2015-12-01)

Pharmacogenetics of HMG-CoA reductase inhibitors (statins): perspectives of individualized, genotype-based therapy
by: D. A. Sychev, et al.
Published: (2006-02-01)

Eupatilin Alleviates Hyperlipidemia in Mice by Inhibiting HMG-CoA Reductase
by: Kyung-Joo Kim, et al.
Published: (2023-01-01)

The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation
by: Paolo Gelosa, et al.
Published: (2007-11-01)

Adverse Effects of HMG CoA Reductase Inhibitor and Garlic on Renal Function in Patients with Diabetic Dyslipidemia
by: Naveed Ali Siddiqui, et al.
Published: (2021-09-01)

Statins: HMG-CoA Reductase Inhibitors as Potential Anticancer Agents against Malignant Neoplasms in Women
by: Anna Markowska, et al.
Published: (2020-11-01)

HMG-CoA Reductase Inhibitor, Simvastatin Is Effective in Decreasing Degree of Myocarditis by Inhibiting Metalloproteinases Activation
by: Monika Skrzypiec-Spring, et al.
Published: (2021-09-01)

Influence of simvA glyzin on expression and inhibition of hmg-coa reductase in rats liver
by: Yu. I. Ragino, et al.
Published: (2015-06-01)

Regulated degradation of HMG CoA reductase requires conformational changes in sterol-sensing domain
by: Hongwen Chen, et al.
Published: (2022-07-01)

Are Point Mutations in HMG-CoA Reductases (Hmg1 and Hmg2) a Step towards Azole Resistance in <i>Aspergillus fumigatus</i>?
by: Irene Gonzalez-Jimenez, et al.
Published: (2021-10-01)

HMG-CoA Reductase Inhibitor Statins Activate the Transcriptional Activity of p53 by Regulating the Expression of TAZ
by: Chiharu Miyajima, et al.
Published: (2022-08-01)

Repositioning of HMG-CoA Reductase Inhibitors as Adjuvants in the Modulation of Efflux Pump-Mediated Bacterial and Tumor Resistance
by: Zsuzsanna Schelz, et al.
Published: (2023-09-01)

Ligand-based pharmacophore modeling, molecular docking, and molecular dynamic studies of HMG-CoA reductase inhibitors
by: Junaidin Junaidin, et al.
Published: (2022-01-01)

Lepidopteran HMG-CoA reductase is a potential selective target for pest control
by: Yuan-mei Li, et al.
Published: (2017-01-01)

An Atomic-Level Perspective of HMG-CoA-Reductase: The Target Enzyme to Treat Hypercholesterolemia
by: Diana S. Gesto, et al.
Published: (2020-08-01)

Molecular docking studies of Triphala with catalytic portion of HMG-CoA reductase enzyme
by: Prasoborn Rinthong, et al.
Published: (2023-04-01)

Hesperidin Interaction with HMG-CoA-Reductase Enzyme in Hypercholesterolemia: A Study in Silico
by: Annisa Rizqi Dwi Oktaviani, et al.
Published: (2021-09-01)

Synergistic effects of HMG‐CoA reductase inhibitor and angiotensin II receptor blocker on load‐induced heart failure
by: Yusuke Ito, et al.
Published: (2018-05-01)

In Silico Characterization of Withania coagulans Bioactive Compounds as Potential Inhibitors of Hydroxymethylglutaryl (HMG-CoA) Reductase of Mus musculus
by: Muhammad Bilal Azmi, et al.
Published: (2023-01-01)

A fungal tolerance trait and selective inhibitors proffer HMG-CoA reductase as a herbicide mode-of-action
by: Joel Haywood, et al.
Published: (2022-09-01)

Studies to elucidate the anti-tumor mechanism of action of risedronate in human myeloma cells; Use of an analogue of risedronate reveals the effects of differential inhibition of prenylation
by: Roelofs, A, et al.
Published: (2005)

Peroxisomal Localization of a Truncated HMG-CoA Reductase under Low Cholesterol Conditions
by: Jianqiu Wang, et al.
Published: (2024-02-01)

The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial
by: Riham M. Karkeet, et al.
Published: (2022-01-01)

The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial.
by: Riham M Karkeet, et al.
Published: (2022-01-01)

HMG-CoA reductase inhibitors in kidney transplant recipients receiving tacrolimus: statins not associated with improved patient or graft survival
by: Schaefer Heidi, et al.
Published: (2010-04-01)

Anti-HMG-CoA reductase myopathy, an undesirable evolution of statin induced myopathy: a case report
by: Sunita Upreti, et al.
Published: (2019-01-01)

The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells
by: B Kwak, et al.
Published: (2001-01-01)